Trial Profile

Phase 1, First-in-Human Study to Assess the Safety, Tolerability and Anti-tumor Activity of CDR404 in HLA-A-02:01 Participants With MAGE-A4 Expressing Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 02 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CDR 404 (Primary)
Indications Bladder cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors CDR-Life

25 Apr 2025 According to CDR-Life media release, dose escalation is ongoing and patient data from the early stages of the Phase 1 trial will be reported later this year.
13 Sep 2024 According to CDR-Life media release, first patient has been dosed in this trial.
29 May 2024 According to CDR-Life media release, company announced that an abstract accepted is for online presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, occurring May 31 - June 4 in Chicago, Illinois.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com